Fastest Hormonal Treatment for Symptomatic Bony Metastatic Prostate Cancer

First-Line Treatment Options

The European guidelines recommend LHRH agonists with antiandrogen coverage as an alternative approach to LHRH antagonists for symptomatic bony metastatic prostate cancer, requiring the addition of an antiandrogen for 3-4 weeks to prevent disease flare due to initial testosterone surge 1, 2
Bilateral orchiectomy provides rapid testosterone reduction within 12-24 hours, but is less commonly chosen due to psychological impact and irreversibility, and is considered a valid option for patients with severe symptoms who need the most rapid relief 3

The National Comprehensive Cancer Network recommends adding antiandrogen coverage for at least 7 days to prevent testosterone flare when using LHRH agonists, such as goserelin or leuprolide, for symptomatic bony metastatic prostate cancer 4
European guidelines specifically recommend antiandrogen coverage for 3-4 weeks when starting LHRH agonist therapy for symptomatic bony metastatic prostate cancer 1, 2

The European guidelines recommend continuous androgen deprivation therapy for metastatic hormone-naïve prostate cancer 5

The National Comprehensive Cancer Network states that combined androgen blockade provides no proven survival benefit over castration alone in metastatic disease but increases side effects 4
Bone-targeted therapy with zoledronic acid or denosumab should be considered for patients with bone metastases from castration-resistant prostate cancer to prevent skeletal-related events 6
Monitoring should include clinical assessment, PSA measurement, and management of side effects, as recommended by the European guidelines 5

Patients with extensive symptomatic bone metastases are at risk for spinal cord compression during testosterone flare with LHRH agonists, making proper antiandrogen coverage crucial, as noted by the National Comprehensive Cancer Network 4